ZSAN Zosano Pharma Corporation

+0.14  (+3%)
Previous Close 4.69
Open 4.67
Price To Book 3.1
Market Cap 57829778
Shares 11,973,039
Volume 1,057,807
Short Ratio
Av. Daily Volume 2,569,201

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
Severe hypoglycemia
NDA filing due 4Q 2019. Phase 3 safety data released February 21, 2019.
Qtrypta (M207)

Latest News

  1. Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
  2. Zosano Pharma Corp. to Host Earnings Call
  3. Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
  4. Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
  5. Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay — What Drives Growth in Today's Competitive Landscape
  6. Four Healthcare Stocks Looking to Close Out a Strong Week
  7. FDA Events Can Send Stocks Soaring: Here's One That Absolutely No One Is Talking About
  8. Watch These Tech Stocks Push The Limit
  9. What Kind Of Shareholder Owns Most Zosano Pharma Corporation (NASDAQ:ZSAN) Stock?
  10. Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease
  11. Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
  12. Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
  13. Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
  14. Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
  15. Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update